

**Publication Instructions:**  
**BMT CTN Protocol 1101**  
**- Primary and Ancillary Studies –**

---

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study 1101. For specific ancillary or correlative studies, contact the email below.

**Acknowledgment Requirements:**

**For all Publications, Reports, Presentations, Symposiums, etc.**

“Support for this study was provided by grant #U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.”

**For correlative studies utilizing biospecimens obtained from the NHLBI Biologic Specimen Repository (operated by the NMDP) and/or clinical data obtained from the NHLBI Data Repository Information Coordinating Center, include the following as applicable:**

If the Research Plan involves collaboration with Study Investigators, acknowledge the source of the data by including language similar to the following either in the acknowledgement or in the text of the manuscript:

*“This manuscript was prepared using BMT CTN 1101 Research Materials obtained from the NHLBI.”*

If the Research Plan does not involve collaboration with Study investigators, or if the Study has ended, use the following language:

*“This manuscript was prepared using BMT CTN 1101 Research Materials obtained from the NHLBI Biologic Specimen and Data Repository (Operated by the NMDP) and NHLBI Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the BMT CTN 01101 or the NHLBI.”*

Manuscripts and abstracts resulting from the Research Plan should not use the name of the Study in the title of the manuscript/abstract unless the title clearly denotes the source of the Research Materials as being from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center.

**The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:**

The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHS234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.

**Review Requirements:**

**For all Publications, Reports, Presentations, Symposiums, etc.**

**BMT CTN:** Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at [NMDP\\_BMTCTN\\_Pub@nmdp.org](mailto:NMDP_BMTCTN_Pub@nmdp.org).